Review
Oncology
Jan Philipp Bewersdorf, Amer M. Zeidan
Summary: MDS and CMML are two distinct blood cancers with variable symptoms and risks. Management decisions should be individualized and based on validated risk stratification tools. Supportive care is the mainstay for lower-risk patients, while bone marrow transplant is the only curative option for higher-risk patients.
Review
Oncology
J. Jian, Y. Qiao, Y. Li, Y. Guo, H. Ma, B. Liu
Summary: CMML, a hematologic malignancy, often transforms into AML and >90% of cases have gene mutations. These mutations are associated with clinical phenotypes and prognosis, with ASXL1 mutations being an independent predictor and potential therapeutic target.
CLINICAL & TRANSLATIONAL ONCOLOGY
(2021)
Article
Oncology
Lulu Wang, Rongrong Chen, Li Li, Lixia Zhu, Xianbo Huang, Xiujin Ye
Summary: In patients with chronic myelomonocytic leukemia (CMML), minimal residual disease (MRD) evaluation has significant prognostic implications. Early MRD negativity after treatment is associated with better clinical outcomes. MRD negativity after initial treatment remains an independent prognostic factor. Risk stratification based on MRD levels can predict patient outcomes.
AMERICAN JOURNAL OF CANCER RESEARCH
(2022)
Article
Medicine, General & Internal
Chao Wang, Zhiqiong Wang, Fankai Meng, Li Luo, Xian Liu, Jiayu Shi, Lifang Huang
Summary: Chronic myelomonocytic leukemia (CMML) is a rare blood malignancy with challenging clinical diagnosis and poor survival rates. Chemotherapy may be the optimal first-line therapy, particularly for patients with 10% or more blast cells in the bone marrow or WHO CMML-2, as it improves overall survival. Gene sequencing provides insights for personalized treatment.
INTERNATIONAL JOURNAL OF GENERAL MEDICINE
(2022)
Article
Oncology
Douglas Tremblay, Noa Rippel, Jonathan Feld, Siraj M. El Jamal, John Mascarenhas
Summary: Chronic myelomonocytic leukemia (CMML) is a hematologic malignancy characterized by monocytosis, dysplasia, and proliferative features. Treatment strategies range from observation to stem cell transplantation, with therapies including hydroxyurea and hypomethylating agents. The recently approved oral decitabine/cedazuridine offers a convenient treatment option. Further research is needed to identify unique targets for CMML therapeutics.
Article
Oncology
Francesca Romana Mauro, Diana Giannarelli, Andrea Visentin, Gianluigi Reda, Paolo Sportoletti, Anna Maria Frustaci, Annalisa Chiarenza, Stefania Ciolli, Candida Vitale, Luca Laurenti, Lorenzo De Paoli, Roberta Murru, Massimo Gentile, Gian Matteo Rigolin, Luciano Levato, Annamaria Giordano, Giovanni Del Poeta, Caterina Stelitano, Claudia Ielo, Alessandro Noto, Valerio Guarente, Stefano Molica, Marta Coscia, Alessandra Tedeschi, Gianluca Gaidano, Antonio Cuneo, Robin Foa, Maurizio Martelli, Corrado Girmenia, Giuseppe Gentile, Livio Trentin
Summary: Ibrutinib has shown superior efficacy compared to chemoimmunotherapy in the treatment of chronic lymphocytic leukemia (CLL). However, adverse events, particularly infections, are a significant concern leading to treatment discontinuation in patients receiving ibrutinib-based therapy. A large study involving 494 CLL patients treated with ibrutinib showed that approximately one-third of patients developed pneumonia or severe infections, with an overall incidence rate of 15.3% per 100 person-year. Patients with a history of severe infection, chronic obstructive pulmonary disease, or extensive prior treatment were more vulnerable to infections. The study also found that infections had a negative impact on treatment discontinuation and survival outcomes.
Review
Oncology
Onyee Chan, Aline Renneville, Eric Padron
Summary: CMML is a rare, heterogeneous myeloid malignancy with challenging diagnosis and a need for more molecular information. Symptom-directed approaches form the basis of management, including pharmacological treatment and transplantation. Early clinical trial results show promise for novel therapies in treating CMML.
Article
Hematology
Mrinal M. Patnaik, Ayalew Tefferi
Summary: Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disorder with overlapping features of myelodysplastic syndromes and myeloproliferative neoplasms. Diagnosis is based on the presence of peripheral blood monocytosis and bone marrow dysplasia. Mutations and risk factors affect prognosis, and hypomethylating agents are commonly used for treatment. Allogeneic stem cell transplant is a potential curative option.
AMERICAN JOURNAL OF HEMATOLOGY
(2022)
Article
Oncology
Gregor Eisenwort, Irina Sadovnik, Alexandra Keller, Daniel Ivanov, Barbara Peter, Daniela Berger, Gabriele Stefanzl, Karin Bauer, Katharina Slavnitsch, Georg Greiner, Karoline V. Gleixner, Wolfgang R. Sperr, Michael Willmann, Heinz Sill, Peter Bettelheim, Klaus Geissler, Michael Deininger, Thomas Rulicke, Peter Valent
Summary: Chronic myelomonocytic leukemia (CMML) is a stem cell-derived neoplasm characterized by dysplasia and uncontrolled expansion of monocytes. Leukemic stem cells (LSC) in CMML are found to reside in a CD34(+)/CD38(-) fraction and express a distinct profile of surface markers. During progression to secondary acute myeloid leukemia (sAML), LSC acquire or upregulate certain cytokine receptors.
Article
Hematology
Jacqueline S. Gonzalez, Maria Agustina Perusini, Ana L. Basquiera, Graciela Alfonso, Dorotea Fantl, Walter Macedo Lima, Elsa Nucifora, Carolina Lazzarino, Viviana Novoa, Marcela Cavalcanti de Andrade Silva, Irene B. Larripa, Vanderson Rocha, Jorge Arbelbide, Elvira D. R. P. Velloso, Carolina B. Belli
Summary: Limited knowledge on chronic myelomonocytic leukemia (CMML) patients from Argentina and Brazil was addressed in this study. The analysis of 280 patients revealed varied clinical characteristics and survival outcomes among different CMML subtypes, highlighting the importance of prognostic assessment. The study validated several scoring systems and the WHO 2016 proposal for predicting outcomes in CMML patients from Latin America.
ANNALS OF HEMATOLOGY
(2021)
Article
Oncology
Yanbo Nie, Liang Shao, Hong Zhang, Colin K. He, Hongyu Li, Junyan Zou, Long Chen, Huaiyue Ji, Hao Tan, Yani Lin, Kun Ru
Summary: CMML patients in China exhibit a unique mutational spectrum, with common mutations in epigenetic modifiers (TET2 and ASXL1), signaling transduction pathway components (NRAS), and splicing factor (SRSF2). DNMT3A, ETV6, FLT3, and NPM1 mutations are associated with progression to sAML. ASXL1 mutation and treatment modalities are independent prognostic factors for CMML.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
(2022)
Article
Immunology
Bihui Pan, Yue Li, Zhangdi Xu, Yi Miao, Hua Yin, Yilin Kong, Xinyu Zhang, Jinhua Liang, Yi Xia, Li Wang, Jianyong Li, Jiazhu Wu, Wei Xu
Summary: A novel prognostic model related to ferroptosis was established for CLL, which can be used for prognostic prediction. The model may also facilitate the development of new clinical ferroptosis-targeted therapies in patients with CLL.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Hematology
Lionel Ades, Larisa Girshova, Vadim A. Doronin, Maria Diez-Campelo, David Valcarcel, Suman Kambhampati, Nora-Athina Viniou, Dariusz Woszczyk, Raquel De Paz Arias, Argiris Symeonidis, Achilles Anagnostopoulos, Eduardo Ciliao Munhoz, Uwe Platzbecker, Valeria Santini, Robert J. Fram, Ying Yuan, Sharon Friedlander, Douglas Faller, Mikkael A. Sekeres
Summary: The study compared the efficacy of pevonedistat+azacitidine to azacitidine monotherapy in patients with newly diagnosed higher-risk myelodysplastic syndromes and found that in certain patient populations, the new treatment may yield better clinical outcomes, while continued therapy could potentially improve survival.
Article
Medicine, General & Internal
Jiamei Ji, Yating Li, Lei Fan, Hua Lu, Xiaoyan Qu
Summary: This report highlights a rare case of pure erythroid leukemia which may present a diagnostic challenge.
Article
Oncology
Annika Kasprzak, Kathrin Nachtkamp, Norbert Gattermann, Ulrich Germing
Summary: This article discusses the prognostic scoring systems for myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). It highlights the limitations of current scoring systems and emphasizes the importance of patient and disease-related parameters in assessing prognosis. The article also identifies areas for further investigation.
Article
Oncology
Andreas Hochhaus, Delphine Rea, Carla Boquimpani, Yosuke Minami, Jorge E. Cortes, Timothy P. Hughes, Jane F. Apperley, Elza Lomaia, Sergey Voloshin, Anna Turkina, Dong-Wook Kim, Andre Abdo, Laura Maria Fogliatto, Philipp le Coutre, Koji Sasaki, Dennis Dong Hwan Kim, Susanne Saussele, Mario Annunziata, Naeem Chaudhri, Lynette Chee, Valentin Garcia-Gutierrez, Shruti Kapoor, Alex Allepuz, Sara Quenet, Veronique Bedoucha, Michael J. Mauro
Summary: Asciminib, a BCR-ABL1 inhibitor that targets the ABL Myristoyl Pocket (STAMP), is approved worldwide for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (CML-CP) who have been previously treated with at least 2 tyrosine kinase inhibitors (TKIs). In the ASCEMBL study, asciminib demonstrated superior efficacy and better safety and tolerability compared to bosutinib in patients with CML-CP who had received at least 2 prior TKIs. The major molecular response rate at week 96 was significantly higher with asciminib than with bosutinib, and fewer adverse events and treatment discontinuations were observed with asciminib.
Article
Hematology
Justin M. Watts, Maria R. Baer, Jay Yang, Thomas Prebet, Sangmin Lee, Gary J. Schiller, Shira N. Dinner, Arnaud Pigneux, Pau Montesinos, Eunice S. Wang, Karen P. Seiter, Andrew H. Wei, Stephane De Botton, Montserrat Arnan, Will Donnellan, Anthony P. Schwarer, Christian Recher, Brian A. Jonas, P. Brent Ferrell Jr, Christophe Marzac, Patrick Kelly, Jennifer Sweeney, Sanjeev Forsyth, Sylvie M. Guichard, Julie Brevard, Patrick Henrick, Hesham Mohamed, Jorge E. Cortes
Summary: This study evaluated the safety, pharmacokinetics, pharmacodynamics, and clinical activity of Olutasidenib in patients with acute myeloid leukemia or myelodysplastic syndrome with mutant IDH1. The results showed that Olutasidenib, as monotherapy or in combination with azacitidine, was well tolerated and exhibited meaningful clinical activity. These findings provide a rationale for further evaluation of Olutasidenib in different populations of patients with myeloid malignancies.
LANCET HAEMATOLOGY
(2023)
Review
Cardiac & Cardiovascular Systems
Nicolas Sayegh, Juliet Yirerong, Neeraj Agarwal, Daniel Addison, Michael Fradley, Jorge Cortes, Neal L. Weintraub, Nazish Sayed, Girindra Raval, Avirup Guha
Summary: The purpose of this review is to provide a detailed overview of the cardiovascular adverse events associated with the use of tyrosine kinase inhibitors in different types of tumors. Recent findings have shown that while tyrosine kinase inhibitors have a survival advantage, they can also cause life-threatening cardiovascular adverse events. Different tyrosine kinase inhibitors have varying cardiovascular toxic profiles, with imatinib possibly being cardioprotective. Vascular endothelial growth factor tyrosine kinase inhibitors are strongly associated with hypertension and arterial ischemic events in the treatment of solid tumors.
CURRENT CARDIOLOGY REPORTS
(2023)
Article
Oncology
Nikhil Shri Sahajpal, Ashis K. Mondal, Harmanpreet Singh, Ashutosh Vashisht, Sudha Ananth, Daniel Saul, Alex R. Hastie, Benjamin Hilton, Barbara R. DuPont, Natasha M. Savage, Vamsi Kota, Alka Chaubey, Jorge E. Cortes, Ravindra Kolhe
Summary: The current genetic testing of myeloid cancers lacks resolution and is limited to specific genomic regions/genes. This study used a combination of high-resolution cytogenetic technology and next-generation sequencing to obtain a comprehensive genomic profile of these tumors. The combinatorial approach identified new genetic alterations and clinically relevant alterations in previously negative cases.
Article
Oncology
May Garrett, Beverly Knight, Jorge E. Cortes, Michael W. Deininger
Summary: This study compared the impact of different doses of bosutinib on the efficacy and safety outcomes of patients with chronic phase chronic myeloid leukemia. The results showed that a starting dose of 400 mg QD had better tolerability and did not compromise efficacy compared to a dose of 500 mg QD.
Article
Economics
Jorge E. Cortes, Delphine Rea, Michael J. Mauro, Diana Tran, Pearl Wang, Kejal Jadhav, Aurore Yocolly, Koji Sasaki
Summary: This study assessed and compared the health care resource utilization (HCRU) rates of asciminib and bosutinib among 3 L+ patients with chronic myeloid leukemia in chronic phase (CML-CP) in the ASCEMBL trial. The results showed that asciminib-treated patients had lower resource utilization compared to bosutinib-treated patients over the long-term.
JOURNAL OF MEDICAL ECONOMICS
(2023)
Review
Hematology
Marisol Miranda-Galvis, Kellen C. Tjioe, E. Andrew Balas, Gagan Agrawal, Jorge E. Cortes
Summary: This article evaluates the impact of social determinants of health on the outcomes of patients with hematologic malignancies. The study found that factors such as education level, health insurance coverage, income level, and marital status significantly affect patients' survival rates. However, there are contradictory reports regarding the effect of distance to treatment centers on treatment outcomes. Additionally, data on transportation, debt, diet, and other factors are lacking.
Article
Biotechnology & Applied Microbiology
Himani Vaidya, Hye Seon Jeong, Kelsey Keith, Shinji Maegawa, Gennaro Calendo, Jozef Madzo, Jaroslav Jelinek, Jean-Pierre J. Issa
Summary: DNA methylation drift and increased entropy with age are primarily caused by and are sensors for, stem cell replication in adult tissues. These findings have implications for tissue-specific functional declines with aging and the development of DNA-methylation-based biological clocks.
Meeting Abstract
Oncology
Michael Mauro, Andreas Hochhaus, Timothy Hughes, Delphine Rea, Carla Boquimpani, Yosuke Minami, Jane Apperley, Valentin Garcia-Gutierrez, Shruti Kapoor, Noemi Espurz, Vishal Dhamal, Jorge Cortes
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Meeting Abstract
Oncology
Marisol Miranda-Galvis, Kellen Tjioe, Andrew Balas, Gagan Agrawal, Jorge Cortes
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Meeting Abstract
Oncology
Martin C. Mueller, Jorge Cortes, Charles Chuah, Daniel J. DeAngelo, Michael Deininger, Francois Guilhot, Timothy Hughes, Franck E. Nicolini, Javier Pinilla-Ibarz, Delphine Rea, Gianantonio Rosti, Neil P. Shah, Moshe Talpaz, Vickie Lu, Thihan Padukkavidana, Hagop M. Kantarjian
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Meeting Abstract
Oncology
Jane Apperley, Jorge Cortes, Elias Jabbour, Andreas Hochhaus, Timothy Hughes, Charles Chuah, Hugues de Lavallade, Michael Deininger, Jeffrey H. Lipton, Elza Lomaia, Lori Maness, Michael Mauro, James McCloskey, Beatriz Moiraghi, Carolina Pavlovsky, Christine Rojas, Philippe Rousselot, Tomasz Sacha, Moshe Talpaz, Anna Turkina, Maria Undurraga Sutton, Xiaowei Ren, Alexander Vorog, Gianantonio Rosti
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Meeting Abstract
Oncology
Ehab Atallah, Michael Mauro, Koji Sasaki, Moshe Levy, Paul Koller, Daisy Yang, Dramane Laine, John Sabo, Ennan Gu, Jorge Cortes
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Meeting Abstract
Oncology
Aram Bidikian, Sreyashi Basu, Zhong He, Himachandana Atluri, Jabra Zarka, Michael Andreeff, Koji Sasaki, Elias Jabbour, Jorge E. Cortes, Padmanee Sharma, Ghayas C. Issa
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Meeting Abstract
Oncology
Joannie Clements, Cristina Ruiz, Andrea Damon, Peter Schuld, Pauline Frank, Cristina Constantinescu, Jorge Cortes
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)